PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety.

Crabb, Simon J; Khalid, Taha; Woods, Lois; Frampton, Geoff; Shepherd, Jonathan

Crabb, Simon J; Khalid, Taha; Woods, Lois; Frampton, Geoff; Shepherd, Jonathan.

Afiliação

Crabb SJ; School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Khalid T; Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Woods L; Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Frampton G; Southampton Health Technology Assessments Centre, Faculty of Medicine, University of Southampton, Southampton, UK.
Shepherd J; Southampton Health Technology Assessments Centre, Faculty of Medicine, University of Southampton, Southampton, UK.

Bladder Cancer ; 9(4): 365-376, 2023.

Article em En | MEDLINE | ID: mdl-38994249

Palavras-chave

Bladder cancer; PARP inhibitor; biomarker; homologous recombination deficiency; immunotherapy; maintenance therapy; systematic review; urothelial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article